Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

HemaQuest Pharmaceuticals (San Diego,CA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease and beta thalassemia closed a $13M Series B financing, bringing the total round to $25M. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures. Note: Closing out 1Q deals. Thanx for your patience as [...]

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $15M Series D financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital, CVF and Bessemer Venture Partners.

Sutro Biopharma (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on partnering and developing proprietary protein therapeutics that have site directed modifications, closed a $36.5M Series C financing. Participants include Skyline Ventures, Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners.

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $24M million Series C financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners.

Cylene Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on multiple myeloma, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments.

Cylene Pharmaceuticals (Sa Diego, CA) a clinical-stage small molecule company focused on broad spectrum anti-proliferative activity against diverse cancer set of cancers, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures and Morningside Venture Investments.

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]

Forma Therapeutics (Cambridge, MA) a development-stage screening and discovery company focused on cancer therapies, closed a $25.5M Series B financing. Participants include Lilly Ventures, Novartis Option Fund and Bio*One Capital. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

  

to top of page...